LFST LifeStance Health Group, Inc.

Nasdaq lifestance.com


$ 6.19 $ 0.00 (0 %)    

Thursday, 20-Nov-2025 15:55:13 EST
QQQ $ 586.90 $ -14.20 (-2.37 %)
DIA $ 458.77 $ -3.66 (-0.79 %)
SPY $ 653.92 $ -10.10 (-1.52 %)
TLT $ 89.27 $ 0.35 (0.39 %)
GLD $ 374.83 nm (nm)
$ 6.18
$ 6.23
$ 6.16 x 604
$ 6.17 x 356
$ 6.12 - $ 6.36
$ 3.74 - $ 8.30
1,689,948
na
2.4B
$ 1.21
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-07-2025 03-31-2025 10-Q
4 02-27-2025 12-31-2024 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 02-28-2024 12-31-2023 10-K
9 11-08-2023 09-30-2023 10-Q
10 08-09-2023 06-30-2023 10-Q
11 05-10-2023 03-31-2023 10-Q
12 03-09-2023 12-31-2022 10-K
13 11-09-2022 09-30-2022 10-Q
14 08-10-2022 06-30-2022 10-Q
15 05-11-2022 03-31-2022 10-Q
16 03-17-2022 12-31-2021 10-K
17 11-10-2021 09-30-2021 10-Q
18 08-12-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 bmo-capital-initiates-coverage-on-lifestance-health-gr-with-outperform-rating-announces-price-target-of-8

BMO Capital analyst Sean Dodge initiates coverage on LifeStance Health Gr (NASDAQ:LFST) with a Outperform rating and announc...

 ubs-maintains-buy-on-lifestance-health-gr-raises-price-target-to-10

UBS analyst Kevin Caliendo maintains LifeStance Health Gr (NASDAQ:LFST) with a Buy and raises the price target from $9 to $10.

 lifestance-health-gr-sees-q4-sales-368000m-388000m-vs-379839m-est

LifeStance Health Gr (NASDAQ:LFST) sees Q4 sales of $368.000 million-$388.000 million vs $379.839 million analyst estimate.

 lifestance-health-gr-lowers-fy2025-sales-guidance-from-1400b-1440b-to-1140b-1430b-vs-1414b-est

LifeStance Health Gr (NASDAQ:LFST) lowers FY2025 sales outlook from $1.400 billion-$1.440 billion to $1.140 billion-$1.430 bill...

 lifestance-health-gr-q3-eps-000-beats-001-estimate-sales-363809m-beat-355604m-estimate

LifeStance Health Gr (NASDAQ:LFST) reported quarterly earnings of $0.00 per share which beat the analyst consensus estimate of ...

 ubs-maintains-buy-on-lifestance-health-gr-raises-price-target-to-9

UBS analyst Kevin Caliendo maintains LifeStance Health Gr (NASDAQ:LFST) with a Buy and raises the price target from $8.5 to $9.

 lifestance-health-gr-affirms-fy2025-sales-guidance-of-1400b-1440b-vs-1413b-est

2025 GuidanceLifeStance is providing the following outlook for 2025:The Company is reiterating full year revenue of $1.40 billi...

 ubs-upgrades-lifestance-health-gr-to-buy-announces-85-price-target

UBS analyst Kevin Caliendo upgrades LifeStance Health Gr (NASDAQ:LFST) from Neutral to Buy and announces $8.5 price target.

 lifestance-health-gr-sees-q2-sales-332000m-352000m-vs-35276m-est

LifeStance Health Gr (NASDAQ:LFST) sees Q2 sales of $332.000 million-$352.000 million vs $352.76 million analyst estimate.

 lifestance-health-gr-affirms-fy2025-sales-guidance-of-140b-144b-vs-142b-est

LifeStance Health Gr (NASDAQ:LFST) affirms FY2025 sales outlook from $1.40 billion-$1.44 billion to $1.40 billion-$1.44 billion...

 lifestance-health-gr-q1-sales-33297m-beat-33290m-estimate

LifeStance Health Gr (NASDAQ:LFST) reported quarterly sales of $332.97 million which beat the analyst consensus estimate of $33...

 keybanc-initiates-coverage-on-lifestance-health-gr-with-overweight-rating-announces-price-target-of-9

Keybanc analyst Steve Dechert initiates coverage on LifeStance Health Gr (NASDAQ:LFST) with a Overweight rating and announc...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION